Synaptogenix, INC

TAO Synergies Inc. stockholders approved an increase of 500,000 shares to its 2020 Equity Incentive Plan, authorized common stock issuance for convertible securities, and re-elected a director at its Annual Meeting.

TAO Synergies Inc. announced an $11 million private placement of Series E convertible preferred stock and warrants, backed by existing investors, James Altucher, and new strategic investor DCG, to fund general corporate purposes and working capital.

TAO Synergies Inc. announced board resignations and a new appointment, alongside engaging Joseph Jacks as an advisor for its AI-focused crypto treasury strategy.

TAO Synergies Inc. stockholders approved a significant increase in the company's equity incentive plan shares and authorized the issuance of common stock underlying convertible preferred stock and warrants.

TAO Synergies Inc. announced the accumulation of 42,111 Bittensor (TAO) tokens, solidifying its position as a leading decentralized AI digital asset treasury company.

A digital asset treasury company announced a significant acquisition of decentralized AI tokens, positioning itself as the largest publicly traded pure-play holder in the Bittensor ecosystem.

TAO Synergies reports Q1 2026 net income of $4.25 million, driven by unrealized gains on its Bittensor (TAO) cryptocurrency treasury holdings.

TAO Synergies Inc. reports a significant net loss for Q3 2025, driven by its pivot to an AI crypto treasury strategy and related expenses, while discontinuing prior drug development programs.

TAO Synergies Inc. has officially shifted its business strategy from biopharmaceuticals to a cryptocurrency treasury focused on Bittensor's TAO token, reporting a significant net loss of $17.1 million for the first half of 2025.

Synaptogenix reports a net income of $385,169 for Q1 2025, shifting from a loss in the previous year, while exploring strategic alternatives and managing cash reserves.

Synaptogenix's Q3 2024 report details financial results, ongoing clinical trials, and recent financing activities, including a new preferred stock offering.

Synaptogenix, Inc. reports a net loss of $1.48 million for the six months ended June 30, 2024, while continuing to advance its clinical development programs.

Tao Synergies Inc. filed an amendment to its 2025 Annual Report to correct the auditor's description of a critical audit matter regarding preferred stock derivative liabilities.

TAO Synergies Inc. has shifted its core business from biopharmaceutical development to a cryptocurrency treasury strategy focused on Bittensor's TAO token, reporting a significant unrealized loss on digital assets for 2025.

Synaptogenix reports its 2024 financial results and continues to explore strategic options to enhance shareholder value, including evaluating drug development platforms and new technologies.

Synaptogenix's 2023 10-K filing details its financial status, ongoing clinical trials, strategic investments, and risk factors, highlighting a year of significant activity and challenges.

Executive Chairman Joshua Silverman received a grant of 200,000 stock options in TAO Synergies Inc. exercisable at $4.80.

Director Bruce Bernstein was granted 55,000 stock options in TAO Synergies Inc. with an exercise price of $4.80.

Director William S. Singer was granted 35,000 stock options in TAO Synergies Inc. with an exercise price of $4.80.

TAO Synergies Inc. CFO Robert Weinstein was granted 30,000 stock options exercisable at $4.80 per share.

Director Robert Ephron of TAO Synergies Inc. was granted 10,000 stock options with an exercise price of $4.80.

TAO Synergies Inc. director William S. Singer acquired 800 stock options with an exercise price of $5.52, vesting one year after April 7, 2026.

TAO Synergies Inc. calls for its 2025 annual meeting to vote on a director election, authorization of common stock issuance for a recent financing, an increase in its equity incentive plan, and auditor ratification.

TAO Synergies Inc. issued a supplement to its definitive proxy statement, detailing new stock option awards for board and management and clarifying voting procedures for its upcoming August 6, 2025 Special Meeting.

TAO Synergies Inc. is seeking stockholder approval for a significant dilutive financing transaction to fund a new AI cryptocurrency treasury strategy and to expand its equity incentive plan, with a special meeting scheduled for August 6, 2025.

Synaptogenix has issued a supplemental proxy statement and corrected proxy card due to an error in the original proxy card which incorrectly listed director nominees.

Synaptogenix is holding its 2024 annual meeting of stockholders on December 6, 2024, to vote on director elections, a share issuance proposal, an equity incentive plan amendment, and ratification of the company's accounting firm.